Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
221-240 of 847 trials

Myotonic Dystrophy Type 1: VX-670 Study

We are testing the safety and tolerability of a new drug, VX-670, in adults with myotonic dystrophy type 1. This study aims to understand how the drug works in the body and its potential benefits.

Myotonic DystrophySafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Achondroplasia: TransCon CNP Treatment for Infants

We are investigating the safety and growth effects of weekly injections of TransCon CNP in infants with achondroplasia. This study aims to understand how the treatment may help with growth and development.

Achondroplasia1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementEndocrinologyPediatrics

Achondroplasia: Infigratinib for Children

We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.

Achondroplasia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Efgartigimod PH20 SC for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will help us understand the right dose and evaluate its safety and effects on daily life.

Myasthenia Gravis3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Neonatal OTC Deficiency: ECUR-506 Treatment Study

We are investigating a new treatment called ECUR-506 for boys under 9 months with neonatal onset OTC deficiency. The study will help us understand its safety and how well it works.

Ornithine Transcarbamylase Deficiency6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

Carbetocin Nasal Spray for Hunger in Prader-Willi Syndrome

We are studying the safety of carbetocin nasal spray for people with Prader-Willi Syndrome who experience uncontrollable hunger. The trial also looks at how this treatment may help with anxiety and caregiver challenges.

Hyperphagia>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesEndocrinologyPediatrics

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Mirikizumab for Children with Ulcerative Colitis or Crohn’s Disease

We are studying the long-term effects of mirikizumab in children and adolescents with moderate-to-severe ulcerative colitis or Crohn’s disease. This research aims to see how well the treatment works for these conditions.

Crohn’s DiseaseUlcerative ColitisInflammatory Bowel DiseasesConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Advanced Head and Neck Cancer: Volrustomig Treatment Study

We are studying whether volrustomig is safe and effective for adults with advanced head and neck cancer who have recently completed chemoradiotherapy without surgery. This trial compares the treatment to observation to see which approach may help patients more.

Unresected Locally Advanced Head and Neck Squamous Cell CarcinomaConfirmation phase (III)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOtolaryngology

Plaque Psoriasis in Teens: Deucravacitinib Study

We are evaluating a new medication for adolescents with moderate to severe plaque psoriasis to see if it helps improve their skin condition compared to a placebo. The study also looks at safety and how patients feel about their treatment.

Plaque Psoriasis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Melanoma Treatment: Pembrolizumab with New Agents

We are studying the safety and effectiveness of pembrolizumab alone or with new investigational treatments for people with melanoma. This research aims to find better options for managing this type of skin cancer.

Melanoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Long-Term Safety Study of Ongoing Treatment with Study Drugs

We are providing continued access to a study drug for patients who are benefiting from it. The goal is to monitor its long-term safety as they continue treatment.

Metastatic Breast CancerMetastatic Non-Small Cell Lung CancerHER2 Positive Breast CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Plaque Psoriasis: Bimekizumab Study

We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.

Plaque PsoriasisPsoriatic Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesDermatologyRheumatology

Chronic Kidney Disease: Baxdrostat with Dapagliflozin

We are studying whether the combination of baxdrostat and dapagliflozin is more effective than dapagliflozin alone for adults with chronic kidney disease and high blood pressure. The trial will assess its impact on kidney health and heart-related risks.

Chronic Kidney DiseaseHypertension>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNephrology

Repotrectinib for Advanced Cancers in Kids and Young Adults

We are studying a new treatment for children and young adults with advanced cancers that have specific genetic changes. The trial aims to evaluate how well it works and its safety.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Chronic Inflammatory Demyelinating Polyneuropathy: Riliprubart Study

We are testing the new medication riliprubart in people with CIDP who haven't found relief from usual treatments. The study will help us understand its effects on disability, quality of life, and safety.

Chronic Inflammatory Demyelinating Polyneuropathy6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementNeurology

Colorectal Cancer: Amivantamab Treatment Study

We are studying the effects of amivantamab alone and with standard chemotherapy for patients with advanced colorectal cancer. The goal is to see how well it works and to ensure it is safe.

Advanced or Metastatic Colorectal CancerSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Parkinson's Disease: AAV2-GDNF Treatment Study

We are studying a new therapy to see if it can improve motor symptoms in adults with moderate Parkinson's Disease. The trial also looks at safety and overall quality of life for participants.

Parkinson's Disease>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurology